U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949799) titled 'A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION' on Nov. 15.

Brief Summary: This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function

Study Start Date: Dec. 17

Study Type: INTERVENTIONAL

Condition: Hepatic Impairment

Intervention: DRUG: FXS6837 capsule

Mild hepatic impairment, FXS6837 125mg orally once.

Recruitment Stat...